OBJECTIVE: Recently, Christianson syndrome (CS) has been determined to be caused by mutations in the X-linked Na(+) /H(+) exchanger 6 (NHE6). We aimed to determine the diagnostic criteria and mutational spectrum for CS. METHODS: Twelve independent pedigrees (14 boys, age = 4-19 years) with mutations in NHE6 were administered standardized research assessments, and mutations were characterized. RESULTS: The mutational spectrum was composed of 9 single nucleotide variants, 2 indels, and 1 copy number variation deletion. All mutations were protein-truncating or splicing mutations. We identified 2 recurrent mutations (c.1498 c>t, p.R500X; and c.1710 g>a, p.W570X). Otherwise, all mutations were unique. In our study, 7 of 12 mutations (58%) were de novo, in contrast to prior literature wherein mutations were largely inherited. We also report prominent neurological, medical, and behavioral symptoms. All CS participants were nonverbal and had intellectual disability, epilepsy, and ataxia. Many had prior diagnoses of autism and/or Angelman syndrome. Other neurologic symptoms included eye movement abnormalities (79%), postnatal microcephaly (92%), and magnetic resonance imaging evidence of cerebellar atrophy (33%). Regression was noted in 50%, with recurrent presentations involving loss of words and/or the ability to walk. Medical symptoms, particularly gastrointestinal symptoms, were common. Height and body mass index measures were below normal ranges in most participants. Behavioral symptoms included hyperkinetic behavior (100%), and a majority exhibited high pain threshold. INTERPRETATION: This is the largest cohort of independent CS pedigrees reported. We propose diagnostic criteria for CS. CS represents a novel neurogenetic disorder with general relevance to autism, intellectual disability, Angelman syndrome, epilepsy, and regression.
OBJECTIVE: Recently, Christianson syndrome (CS) has been determined to be caused by mutations in the X-linked Na(+) /H(+) exchanger 6 (NHE6). We aimed to determine the diagnostic criteria and mutational spectrum for CS. METHODS: Twelve independent pedigrees (14 boys, age = 4-19 years) with mutations in NHE6 were administered standardized research assessments, and mutations were characterized. RESULTS: The mutational spectrum was composed of 9 single nucleotide variants, 2 indels, and 1 copy number variation deletion. All mutations were protein-truncating or splicing mutations. We identified 2 recurrent mutations (c.1498 c>t, p.R500X; and c.1710 g>a, p.W570X). Otherwise, all mutations were unique. In our study, 7 of 12 mutations (58%) were de novo, in contrast to prior literature wherein mutations were largely inherited. We also report prominent neurological, medical, and behavioral symptoms. All CS participants were nonverbal and had intellectual disability, epilepsy, and ataxia. Many had prior diagnoses of autism and/or Angelman syndrome. Other neurologic symptoms included eye movement abnormalities (79%), postnatal microcephaly (92%), and magnetic resonance imaging evidence of cerebellar atrophy (33%). Regression was noted in 50%, with recurrent presentations involving loss of words and/or the ability to walk. Medical symptoms, particularly gastrointestinal symptoms, were common. Height and body mass index measures were below normal ranges in most participants. Behavioral symptoms included hyperkinetic behavior (100%), and a majority exhibited high pain threshold. INTERPRETATION: This is the largest cohort of independent CS pedigrees reported. We propose diagnostic criteria for CS. CS represents a novel neurogenetic disorder with general relevance to autism, intellectual disability, Angelman syndrome, epilepsy, and regression.
Authors: Janneke H M Schuurs-Hoeijmakers; Anneke T Vulto-van Silfhout; Lisenka E L M Vissers; Ilse I G M van de Vondervoort; Bregje W M van Bon; Joep de Ligt; Christian Gilissen; Jayne Y Hehir-Kwa; Kornelia Neveling; Marisol del Rosario; Gausiya Hira; Santina Reitano; Aurelio Vitello; Pinella Failla; Donatella Greco; Marco Fichera; Ornella Galesi; Tjitske Kleefstra; Marie T Greally; Charlotte W Ockeloen; Marjolein H Willemsen; Ernie M H F Bongers; Irene M Janssen; Rolph Pfundt; Joris A Veltman; Corrado Romano; Michèl A Willemsen; Hans van Bokhoven; Han G Brunner; Bert B A de Vries; Arjan P M de Brouwer Journal: J Med Genet Date: 2013-10-11 Impact factor: 6.318
Authors: A Riess; E Rossier; R Krüger; A Dufke; S Beck-Woedl; V Horber; M Alber; D Gläser; O Riess; A Tzschach Journal: Clin Genet Date: 2012-08-30 Impact factor: 4.438
Authors: R J Kuczmarski; C L Ogden; L M Grummer-Strawn; K M Flegal; S S Guo; R Wei; Z Mei; L R Curtin; A F Roche; C L Johnson Journal: Adv Data Date: 2000-06-08
Authors: Kathleen J Motil; Erwin Caeg; Judy O Barrish; Suzanne Geerts; Jane B Lane; Alan K Percy; Fran Annese; Lauren McNair; Steven A Skinner; Hye-Seung Lee; Jeffrey L Neul; Daniel G Glaze Journal: J Pediatr Gastroenterol Nutr Date: 2012-09 Impact factor: 2.839
Authors: Qing Ouyang; Sofia B Lizarraga; Michael Schmidt; Unikora Yang; Jingyi Gong; Debra Ellisor; Julie A Kauer; Eric M Morrow Journal: Neuron Date: 2013-09-12 Impact factor: 17.173
Authors: Christina A Markunas; Kaia S Quinn; Ann L Collins; Melanie E Garrett; Ave M Lachiewicz; Jennifer L Sommer; Erin Morrissey-Kane; Scott H Kollins; Arthur D Anastopoulos; Allison E Ashley-Koch Journal: Psychiatr Genet Date: 2010-04 Impact factor: 2.458
Authors: Petter Strømme; Kostantin Dobrenis; Roy V Sillitoe; Maria Gulinello; Nafeeza F Ali; Cristin Davidson; Matthew C Micsenyi; Gloria Stephney; Linda Ellevog; Arne Klungland; Steven U Walkley Journal: Brain Date: 2011-09-29 Impact factor: 13.501
Authors: Andrew S Allen; Samuel F Berkovic; Patrick Cossette; Norman Delanty; Dennis Dlugos; Evan E Eichler; Michael P Epstein; Tracy Glauser; David B Goldstein; Yujun Han; Erin L Heinzen; Yuki Hitomi; Katherine B Howell; Michael R Johnson; Ruben Kuzniecky; Daniel H Lowenstein; Yi-Fan Lu; Maura R Z Madou; Anthony G Marson; Heather C Mefford; Sahar Esmaeeli Nieh; Terence J O'Brien; Ruth Ottman; Slavé Petrovski; Annapurna Poduri; Elizabeth K Ruzzo; Ingrid E Scheffer; Elliott H Sherr; Christopher J Yuskaitis; Bassel Abou-Khalil; Brian K Alldredge; Jocelyn F Bautista; Samuel F Berkovic; Alex Boro; Gregory D Cascino; Damian Consalvo; Patricia Crumrine; Orrin Devinsky; Dennis Dlugos; Michael P Epstein; Miguel Fiol; Nathan B Fountain; Jacqueline French; Daniel Friedman; Eric B Geller; Tracy Glauser; Simon Glynn; Sheryl R Haut; Jean Hayward; Sandra L Helmers; Sucheta Joshi; Andres Kanner; Heidi E Kirsch; Robert C Knowlton; Eric H Kossoff; Rachel Kuperman; Ruben Kuzniecky; Daniel H Lowenstein; Shannon M McGuire; Paul V Motika; Edward J Novotny; Ruth Ottman; Juliann M Paolicchi; Jack M Parent; Kristen Park; Annapurna Poduri; Ingrid E Scheffer; Renée A Shellhaas; Elliott H Sherr; Jerry J Shih; Rani Singh; Joseph Sirven; Michael C Smith; Joseph Sullivan; Liu Lin Thio; Anu Venkat; Eileen P G Vining; Gretchen K Von Allmen; Judith L Weisenberg; Peter Widdess-Walsh; Melodie R Winawer Journal: Nature Date: 2013-08-11 Impact factor: 49.962
Authors: Christelle M El Achkar; Heather E Olson; Annapurna Poduri; Phillip L Pearl Journal: Curr Neurol Neurosci Rep Date: 2015-07 Impact factor: 5.081
Authors: Matthew F Pescosolido; Brian C Kavanaugh; Nathalie Pochet; Michael Schmidt; Beth A Jerskey; Jeffrey M Rogg; Philip L De Jager; Tracy L Young-Pearse; Judy S Liu; Eric M Morrow Journal: Mol Neuropsychiatry Date: 2019-03-06
Authors: Ece D Gamsiz; Laura N Sciarra; Abbie M Maguire; Matthew F Pescosolido; Laura I van Dyck; Eric M Morrow Journal: Neurotherapeutics Date: 2015-07 Impact factor: 7.620